Combination Immunotherapy Enhances Anti-Cancer Immunity in Mice with Gastric Cancer
Author Information
Author(s): Natasja K van den Engel, Dominik Rüttinger, Margareta Rusan, Robert Kammerer, Wolfgang Zimmermann, Rudolf A Hatz, Hauke Winter
Primary Institution: Ludwig-Maximilians-University, Munich, Germany
Hypothesis
Can combining active-specific tumor cell vaccination with lymphodepletion and GM-CSF enhance anti-tumor immunity in gastric cancer?
Conclusion
The study found that a combination of tumor cell vaccination, lymphodepletion, and GM-CSF significantly enhances anti-tumor immunity in a mouse model of gastric cancer.
Supporting Evidence
- LRAST treatment resulted in 80% of mice being tumor-free compared to 20% in the control group.
- The combination of cyclophosphamide and GM-CSF significantly increased tumor-specific T cell responses.
- A transient decrease in regulatory T cells was observed following LRAST treatment.
Takeaway
Researchers found that a special treatment helped mice fight off stomach cancer better by using a vaccine and some medicine to boost their immune system.
Methodology
Mice were treated with cyclophosphamide to induce lymphopenia, reconstituted with spleen cells, and vaccinated with a whole tumor cell vaccine combined with GM-CSF.
Potential Biases
Potential bias due to the use of a single mouse model and the specific treatment regimen.
Limitations
The long-term efficacy may be affected by the recurrence of regulatory T cells.
Participant Demographics
C57BL/6 mice, 8-12 weeks old, female.
Statistical Information
P-Value
0.045
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website